Progyny’s (PGNY) “Hold” Rating Reiterated at Truist Financial

Progyny (NASDAQ:PGNY)‘s stock had its “hold” rating reissued by equities research analysts at Truist Financial in a report released on Wednesday,Benzinga reports. They presently have a $19.00 price target on the stock, down from their prior price target of $26.00. Truist Financial’s target price suggests a potential upside of 10.59% from the company’s previous close.

A number of other analysts have also weighed in on the company. Canaccord Genuity Group lowered Progyny from a “buy” rating to a “hold” rating and dropped their price objective for the company from $37.00 to $24.00 in a research note on Wednesday, August 7th. Jefferies Financial Group cut their price target on shares of Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, September 19th. Canaccord Genuity Group lowered their price objective on shares of Progyny from $24.00 to $18.00 and set a “hold” rating for the company in a research note on Friday, September 20th. JPMorgan Chase & Co. cut their target price on Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, September 19th. Finally, Leerink Partners lowered their price target on Progyny from $25.00 to $21.00 and set a “market perform” rating for the company in a research report on Thursday, September 19th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.09.

Progyny Trading Up 0.7 %

NASDAQ PGNY opened at $17.18 on Wednesday. The stock has a 50-day moving average of $17.88 and a 200-day moving average of $23.62. Progyny has a 1-year low of $13.93 and a 1-year high of $42.08. The firm has a market cap of $1.55 billion, a PE ratio of 27.27, a price-to-earnings-growth ratio of 1.61 and a beta of 1.44.

Hedge Funds Weigh In On Progyny

Institutional investors and hedge funds have recently made changes to their positions in the business. Pacer Advisors Inc. grew its stake in shares of Progyny by 12,579.4% in the 3rd quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company’s stock worth $41,777,000 after buying an additional 2,472,983 shares during the last quarter. International Assets Investment Management LLC increased its holdings in shares of Progyny by 1,576.0% during the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company’s stock valued at $42,991,000 after acquiring an additional 2,412,068 shares in the last quarter. Farallon Capital Management LLC boosted its stake in Progyny by 120.8% in the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock worth $37,436,000 after purchasing an additional 715,900 shares in the last quarter. Redmile Group LLC purchased a new stake in Progyny during the 1st quarter valued at about $12,241,000. Finally, Dimensional Fund Advisors LP raised its holdings in Progyny by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company’s stock worth $36,676,000 after acquiring an additional 254,725 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.